Clinical trial
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or…
NCT00349206 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00349206 |
|---|---|
| Title | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma |
| Official title | Phase 1 Study of the Combination of BAY 43-9006 (Sorafenib) and CCI-779 (Temsirolimus) in Patients With Metastatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma |
| Intervention type | Drug |
| Interventions | sorafenib tosylate, temsirolimus |
| Enrollment | 69 |
| Start date | Apr 1, 2006 |
| Primary completion | Feb 1, 2012 |
| Completion | Feb 1, 2012 |
| First posted | Jul 6, 2006 |
| Last update posted | Apr 10, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: